Systemic anti-cancer therapy in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC): Insights from National Cancer Registration and Analysis Service (NCRAS)

#4461

Introduction: ENETS advocates the use of platinum-based chemotherapy in combination with Etoposide as first-line chemotherapy in advanced GEP-NEC. Available retrospective evidence is from small studies.

Aim(s): To explore chemotherapy regimens used in England in the last 10 years.

Materials and methods: Patients with GEP-NEC diagnosed between 2012-2021 were extracted from NCRAS and divided into chemotherapy (group-1) or no chemotherapy (group-2). Kaplan Meier (KM) estimated overall survival (OS). Logistic regression was used to evaluate factors associated with receiving chemotherapy.

Conference:

Presenting Author: Mortagy M

Authors: Mortagy M, El Asmar M, Paisey S, White B, Chandrakumaran K,

Keywords: Systemic anti-cancer therapy, Chemotherapy, GEP-NEC, NCRAS,